Technological overview of iPS induction from human adult somatic cells

Current Gene Therapy

Volumn 13, Issue 2, 2013, Pages 73-92

  Bayart, Emilie ^a   Cohen Haguenauer, Odile ^a,b  

^a Ecole Normale Superieure de Cachan   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Gene transfer systems; Genetic instability; Human induced pluripotent stem cells; Regenerative medicine; Reprogramming methods; Stem cells engineering

Indexed keywords

ASCORBIC ACID; DOXYCYCLINE; EPSTEIN BARR VIRUS ANTIGEN; GLYCOGEN SYNTHASE KINASE 3; KRUPPEL LIKE FACTOR 4; LENTIVIRUS VECTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; OCTAMER TRANSCRIPTION FACTOR 4; PLASMID DNA; RETROVIRUS VECTOR; TELOMERASE REVERSE TRANSCRIPTASE; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; TRICHOSTATIN A; VALPROIC ACID; ZINC FINGER NUCLEASE;

3' UNTRANSLATED REGION; CARCINOGENESIS; CELL CYCLE REGULATION; CELL DAMAGE; CELL DIFFERENTIATION; CLINICAL TRIAL (TOPIC); DNA METHYLATION; DNA REPAIR; EMBRYONIC STEM CELL; EPIGENETICS; GENE EXPRESSION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GLIOBLASTOMA; HUMAN; MUTAGENESIS; ONCOGENE C MYC; PHASE 1 CLINICAL TRIAL (TOPIC); PLURIPOTENT STEM CELL; REGENERATIVE MEDICINE; REVIEW; RNA TRANSLATION; SOMATIC GENE THERAPY; TRANSGENE; TRANSPOSON; VIRAL GENE DELIVERY SYSTEM;

ADULT; CELL DIFFERENTIATION; EMBRYONIC STEM CELLS; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENETIC THERAPY; HUMANS; INDUCED PLURIPOTENT STEM CELLS; NOBEL PRIZE; NUCLEAR REPROGRAMMING; REGENERATIVE MEDICINE; TISSUE THERAPY;

ADENOVIRIDAE; IPS; SENDAI VIRUS;

EID: 84876714423     PISSN: 15665232     EISSN: 18755631     Source Type: Journal    
DOI: 10.2174/1566523211313020002     Document Type: Review

References (203)

1. French AJ, Adams CA, Anderson LS, Kitchen JR, Hughes MR, Wood SH. Development of human cloned blastocysts following somatic cell nuclear transfer with adult fibroblasts. Stem Cells 2008; 26(2): 485-493.
2. Gurdon JB, Elsdale TR, Fischberg M. Sexually mature individuals of Xenopus laevis from the transplantation of single somatic nuclei. Nature 1958; 182(4627): 64-65.
3. Gurdon JB, Melton DA. Nuclear reprogramming in cells. Science 2008; 322(5909): 1811-1815.
4. Cowan CA, Atienza J, Melton DA, Eggan K. Nuclear reprogramming of somatic cells after fusion with human embryonic stem cells. Science 2005; 309(5739): 1369-1373.
5. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126(4): 663-676.
6. Avilion AA, Nicolis SK, Pevny LH, Perez L, Vivian N, Lovell- Badge R. Multipotent cell lineages in early mouse development depend on SOX2 function. Genes Dev 2003; 17(1): 126-140.
7. Cartwright P, McLean C, Sheppard A, Rivett D, Jones K, Dalton S. LIF/STAT3 controls ES cell self-renewal and pluripotency by a Myc-dependent mechanism. Development 2005; 132(5): 885-896.
8. Li Y, McClintick J, Zhong L, Edenberg HJ, Yoder MC, Chan RJ. Murine embryonic stem cell differentiation is promoted by SOCS-3 and inhibited by the zinc finger transcription factor Klf4. Blood 2005; 105(2): 635-637.
9. Nichols J, Zevnik B, Anastassiadis K, et al. Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4. Cell 1998; 95(3): 379-391.
10. Niwa H, Miyazaki J, Smith AG. Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. Nat Genet 2000; 24(4): 372-376.
11. Hayashi K, Ogushi S, Kurimoto K, Shimamoto S, Ohta H, Saitou M. Offspring from oocytes derived from in vitro primordial germ cell-like cells in mice. Science 2012; 338(6109): 971-975.
12. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131(5): 861-872.
13. Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007; 318(5858): 1917-1920.
14. Huangfu D, Maehr R, Guo W, et al. Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. Nat Biotechnol 2008; 26(7): 795-797.
15. Shi Y, Do JT, Desponts C, Hahm HS, Scholer HR, Ding S. A combined chemical and genetic approach for the generation of induced pluripotent stem cells. Cell Stem Cell 2008; 2(6): 525-528.
16. Park IH, Lerou PH, Zhao R, Huo H, Daley GQ. Generation of human-induced pluripotent stem cells. Nat Protoc 2008; 3(7): 1180-1186.
17. Gonzalez F, Boue S, Izpisua Belmonte JC. Methods for making induced pluripotent stem cells: reprogramming a la carte. Nat Rev Genet 2011; 12(4): 231-242.
18. Kitamura T, Koshino Y, Shibata F, et al. Retrovirus-mediated gene transfer and expression cloning: powerful tools in functional genomics. Exp Hematol 2003; 31(11): 1007-1014.
19. Aasen T, Raya A, Barrero MJ, et al. Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes. Nat Biotechnol 2008; 26(11): 1276-1284.
20. Hawley RG, Lieu FH, Fong AZ, Hawley TS. Versatile retroviral vectors for potential use in gene therapy. Gene Ther 1994; 1(2): 136-138.
21. Jahner D, Stuhlmann H, Stewart CL, et al. De novo methylation and expression of retroviral genomes during mouse embryogenesis. Nature 1982; 298(5875): 623-628.
22. Stewart CL, Stuhlmann H, Jahner D, Jaenisch R. De novo methylation, expression, and infectivity of retroviral genomes introduced into embryonal carcinoma cells. Proc Natl Acad Sci USA 1982; 79(13): 4098-4102.
23. Nakagawa M, Koyanagi M, Tanabe K, et al. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotechnol 2008; 26(1): 101-106.
24. Matsui T, Leung D, Miyashita H, et al. Proviral silencing in embryonic stem cells requires the histone methyltransferase ESET. Nature 2010; 464(7290): 927-931.
25. Hotta A, Ellis J. Retroviral vector silencing during iPS cell induction: an epigenetic beacon that signals distinct pluripotent states. J Cell Biochem 2008; 105(4): 940-948.
26. Ramos-Mejia V, Montes R, Bueno C, et al. Residual expression of the reprogramming factors prevents differentiation of iPSC generated from human fibroblasts and cord blood CD34+ progenitors. PLoS One 2012; 7(4): e35824.
27. de Felipe P. Skipping the co-expression problem: the new 2A CHYSEL technology. Genet Vaccines Ther 2004; 2(1): 13.
28. Szymczak AL, Vignali DA. Development of 2A peptide-based strategies in the design of multicistronic vectors. Expert Opin Biol Ther 2005; 5 (5): 627-638.
29. Kaji K, Norrby K, Paca A, Mileikovsky M, Mohseni P, Woltjen K. Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature 2009; 458(7239): 771-775.
30. Lin SL, Chang DC, Lin CH, Ying SY, Leu D, Wu DT. Regulation of somatic cell reprogramming through inducible mir-302 expression. Nucleic Acids Res 2011; 39(3): 1054-1065.
31. Huangfu D, Osafune K, Maehr R, et al. Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nat Biotechnol 2008; 26(11): 1269-1275.
32. Shi Y, Desponts C, Do JT, Hahm HS, Scholer HR, Ding S. Induction of pluripotent stem cells from mouse embryonic fibroblasts by Oct4 and Klf4 with small-molecule compounds. Cell Stem Cell 2008; 3(5): 568-574.
33. Buecker C, Chen HH, Polo JM, et al. A murine ESC-like state facilitates transgenesis and homologous recombination in human pluripotent stem cells. Cell Stem Cell 2010; 6 (6): 535-546.
34. Hasegawa K, Zhang P, Wei Z, Pomeroy JE, Lu W, Pera MF. Comparison of reprogramming efficiency between transduction of reprogramming factors, cell-cell fusion, and cytoplast fusion. Stem Cells 2010; 28(8): 1338-1348.
35. Loh YH, Hartung O, Li H, et al. Reprogramming of T cells from human peripheral blood. Cell Stem Cell 2010; 7(1): 15-19.
36. Maherali N, Ahfeldt T, Rigamonti A, Utikal J, Cowan C, Hochedlinger K. A high-efficiency system for the generation and study of human induced pluripotent stem cells. Cell Stem Cell 2008; 3(3): 340-345.
37. Utikal J, Maherali N, Kulalert W, Hochedlinger K. Sox2 is dispensable for the reprogramming of melanocytes and melanoma cells into induced pluripotent stem cells. J Cell Sci 2009; 122(Pt 19): 3502-3510.
38. Varas F, Stadtfeld M, de Andres-Aguayo L, et al. Fibroblastderived induced pluripotent stem cells show no common retroviral vector insertions. Stem Cells 2009; 27(2): 300-306.
39. Kane NM, Nowrouzi A, Mukherjee S, et al. Lentivirus-mediated reprogramming of somatic cells in the absence of transgenic transcription factors. Mol Ther 2010; 18(12): 2139-2145.
40. Carey BW, Markoulaki S, Hanna J, et al. Reprogramming of murine and human somatic cells using a single polycistronic vector. Proc Natl Acad Sci USA 2009; 106(1): 157-162.
41. Rodriguez-Piza I, Richaud-Patin Y, Vassena R, et al. Reprogramming of human fibroblasts to induced pluripotent stem cells under xeno-free conditions. Stem Cells 2010; 28 (1): 36-44.
42. Soldner F, Hockemeyer D, Beard C, et al. Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell 2009; 136(5): 964-977.
43. Chang CW, Lai YS, Pawlik KM, et al. Polycistronic lentiviral vector for hit and run reprogramming of adult skin fibroblasts to induced pluripotent stem cells. Stem Cells 2009; 27(5): 1042-1049.
44. O'Gorman S, Fox DT, Wahl GM. Recombinase-mediated gene activation and site-specific integration in mammalian cells. Science 1991; 251(4999): 1351-1355.
45. Nakano M, Ishimura M, Chiba J, Kanegae Y, Saito I. DNA substrates influence the recombination efficiency mediated by FLP recombinase expressed in mammalian cells. Microbiol Immunol 2001; 45(9): 657-665.
46. Schmidt-Supprian M, Rajewsky K. Vagaries of conditional gene targeting. Nat Immunol 2007; 8(7): 665-668.
47. Voelkel C, Galla M, Maetzig T, et al. Protein transduction from retroviral Gag precursors. Proc Natl Acad Sci USA 2010; 107(17): 7805-7810.
48. Cary LC, Goebel M, Corsaro BG, Wang HG, Rosen E, Fraser MJ. Transposon mutagenesis of baculoviruses: analysis of Trichoplusia ni transposon IFP2 insertions within the FP-locus of nuclear polyhedrosis viruses. Virology 1989; 172(1): 156-169.
49. Fraser MJ, Ciszczon T, Elick T, Bauser C. Precise excision of TTAA-specific lepidopteran transposons piggyBac (IFP2) and tagalong (TFP3) from the baculovirus genome in cell lines from two species of Lepidoptera. Insect Mol Biol 1996; 5(2): 141-151.
50. Fraser MJ, Cary L, Boonvisudhi K, Wang HG. Assay for movement of Lepidopteran transposon IFP2 in insect cells using a baculovirus genome as a target DNA. Virology 1995; 211(2): 397-407.
51. Woltjen K, Michael IP, Mohseni P, et al. piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature 2009; 458(7239): 766-770.
52. Ivics Z, Hackett PB, Plasterk RH, Izsvak Z. Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells. Cell 1997; 91(4): 501-510.
53. Mates L, Chuah MK, Belay E, et al. Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates. Nat Genet 2009; 41(6): 753-761.
54. Iszvak Z, Escobar H, Johen S, Ivics Z, Kusk P, Thumann G. The Sleeping Beauty-based non viral, integrating vector system, the next challenge. e-chips 2011; Paris 73.
55. Belay E, Dastidar S, Vandendriessche T, Chuah MK. Transposon- Mediated Gene Transfer into Adult and Induced Pluripotent Stem Cells. Curr Gene Ther 2011; 11(5): 406-413.
56. Wang W, Lin C, Lu D, et al. Chromosomal transposition of Piggy- Bac in mouse embryonic stem cells. Proc Natl Acad Sci USA 2008; 105(27): 9290-9295.
57. Galla M, Schambach A, Falk CS, et al. Avoiding cytotoxicity of transposases by dose-controlled mRNA delivery. Nucleic Acids Res 2011; 39(16): 7147-7160.
58. Yu SS, Dan K, Chono H, Chatani E, Mineno J, Kato I. Transient gene expression mediated by integrase-defective retroviral vectors. Biochem Biophys Res Commun 2008; 368(4): 942-947.
59. Staunstrup NH, Mikkelsen JG. Integrase-defective lentiviral vectors-- a stage for nonviral integration machineries. Curr Gene Ther 11(5): 350-362.
60. Philippe S, Sarkis C, Barkats M, et al. Lentiviral vectors with a defective integrase allow efficient and sustained transgene expression in vitro and in vivo. Proc Natl Acad Sci USA 2006; 103(47): 17684-17689.
61. Saenz DT, Loewen N, Peretz M, et al. Unintegrated lentivirus DNA persistence and accessibility to expression in nondividing cells: analysis with class I integrase mutants. J Virol 2004; 78(6): 2906-2920.
62. Yanez-Munoz RJ, Balaggan KS, MacNeil A, et al. Effective gene therapy with nonintegrating lentiviral vectors. Nat Med 2006; 12(3): 348-353.
63. Stadtfeld M, Nagaya M, Utikal J, Weir G, Hochedlinger K. Induced pluripotent stem cells generated without viral integration. Science 2008; 322(5903): 945-949.
64. Graham FL, Prevec L. Adenovirus-based expression vectors and recombinant vaccines. Biotechnology 1992; 20: 363-390.
65. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 1998; 95(5): 2509-2514.
66. Zhou W, Freed CR. Adenoviral gene delivery can reprogram human fibroblasts to induced pluripotent stem cells. Stem Cells 2009; 27(11): 2667-2674.
67. Stephen SL, Sivanandam VG, Kochanek S. Homologous and heterologous recombination between adenovirus vector DNA and chromosomal DNA. J Gene Med 2008; 10(11): 1176-1189.
68. Lamb R, Kolakofsky D. Paramyxoviridae: the viruses and their replication. Lippincott Williams & Wilkins, New York 2001; 1177-1204.
69. Tokusumi T, Iida A, Hirata T, Kato A, Nagai Y, Hasegawa M. Recombinant Sendai viruses expressing different levels of a foreign reporter gene. Virus Res 2002; 86 (1-2): 33-38.
70. Li HO, Zhu YF, Asakawa M, et al. A cytoplasmic RNA vector derived from nontransmissible Sendai virus with efficient gene transfer and expression. J Virol 2000; 74(14): 6564-6569.
71. Nakanishi M, Otsu M. Development of Sendai Virus Vectors and their Potential Applications in Gene Therapy and Regenerative Medicine. Curr Gene Ther 2012; 12(5): 410-416.
72. Fusaki N, Ban H, Nishiyama A, Saeki K, Hasegawa M. Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. Proc Jpn Acad Ser B Phys Biol Sci 2009; 85(8): 348-362.
73. Nishishita N, Shikamura M, Takenaka C, Takada N, Fusak N, Kawamata S. Generation of virus-free induced pluripotent stem cell clones on a synthetic matrix via a single cell subcloning in the naïve state. PLoS One 2012; 7(6): e38389.
74. Ono M, Hamada Y, Horiuchi Y, et al. Generation of induced pluripotent stem cells from human nasal epithelial cells using a Sendai virus vector. PLoS One 2012; 7(8): e42855.
75. Seki T, Yuasa S, Fukuda K. Generation of induced pluripotent stem cells from a small amount of human peripheral blood using a combination of activated T cells and Sendai virus. Nat Protoc 2012; 7(4): 718-728.
76. Seki T, Yuasa S, Oda M, et al. Generation of induced pluripotent stem cells from human terminally differentiated circulating T cells. Cell Stem Cell 2010; 7(1): 11-14.
77. Macarthur CC, Fontes A, Ravinder N, et al. Generation of humaninduced pluripotent stem cells by a nonintegrating RNA Sendai virus vector in feeder-free or xeno-free conditions. Stem Cells Int 2012; 2012: 564612.
78. Nishimura K, Sano M, Ohtaka M, et al. Development of defective and persistent Sendai virus vector: a unique gene delivery/expression system ideal for cell reprogramming. J Biol Chem 2011; 286(6): 4760-4771.
79. Griesenbach U, Inoue M, Hasegawa M, Alton EW. Sendai virus for gene therapy and vaccination. Curr Opin Mol Ther 2005; 7(4): 346-352.
80. Gonzalez F, Barragan Monasterio M, Tiscornia G, et al. Generation of mouse-induced pluripotent stem cells by transient expression of a single nonviral polycistronic vector. Proc Natl Acad Sci USA 2009; 106(22): 8918-8922.
81. Okita K, Hong H, Takahashi K, Yamanaka S. Generation of mouse-induced pluripotent stem cells with plasmid vectors. Nat Protoc 2010; 5(3): 418-428.
82. Okita K, Nakagawa M, Hyenjong H, Ichisaka T, Yamanaka S. Generation of mouse induced pluripotent stem cells without viral vectors. Science 2008; 322(5903): 949-953.
83. Si-Tayeb K, Noto FK, Sepac A, et al. Generation of human induced pluripotent stem cells by simple transient transfection of plasmid DNA encoding reprogramming factors. BMC Dev Biol 2010; 10: 81.
84. Montserrat N, Garreta E, Gonzalez F, et al. Simple generation of human induced pluripotent stem cells using poly-beta-amino esters as the non-viral gene delivery system. J Biol Chem 2011; 286 (14): 12417-12428.
85. Yu J, Hu K, Smuga-Otto K, et al. Human induced pluripotent stem cells free of vector and transgene sequences. Science 2009; 324(5928): 797-801.
86. Yates J, Warren N, Reisman D, Sugden B. Acis-acting element from the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in latently infected cells. Proc Natl Acad Sci USA 1984; 81(12): 3806-3810.
87. Yates JL, Warren N, Sugden B. Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature 1985; 313(6005): 812-815.
88. Okita K, Matsumura Y, Sato Y, et al. A more efficient method to generate integration-free human iPS cells. Nat Methods 2011; 8(5): 409-412.
89. Chou BK, Mali P, Huang X, et al. Efficient human iPS cell derivation by a non-integrating plasmid from blood cells with unique epigenetic and gene expression signatures. Cell Res 2011; 21(3): 518-529.
90. Chen ZY, He CY, Ehrhardt A, Kay MA. Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo. Mol Ther 2003; 8(3): 495-500.
91. Chen ZY, He CY, Kay MA. Improved production and purification of minicircle DNA vector free of plasmid bacterial sequences and capable of persistent transgene expression in vivo. Hum Gene Ther 2005; 16(1): 126-131.
92. Jia F, Wilson KD, Sun N, et al. A nonviral minicircle vector for deriving human iPS cells. Nat Methods 2010; 7(3): 197-199.
93. Narsinh KH, Jia F, Robbins RC, Kay MA, Longaker MT, Wu JC. Generation of adult human induced pluripotent stem cells using nonviral minicircle DNA vectors. Nat Protoc 2011; 6(1): 78-88.
94. Plews JR, Li J, Jones M, Moore HD, Mason C, Andrews PW, Na J. Activation of pluripotency genes in human fibroblast cells by a novel mRNA based approach. PLoS One 2010; 5(12): e14397.
95. Yakubov E, Rechavi G, Rozenblatt S, Givol D. Reprogramming of human fibroblasts to pluripotent stem cells using mRNA of four transcription factors. Biochem Biophys Res Commun 2010; 394(1): 189-193.
96. Warren L, Manos PD, Ahfeldt T, et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 2010; 7(5): 618-630.
97. Warren L, Ni Y, Wang J, Guo X. Feeder-free derivation of human induced pluripotent stem cells with messenger RNA. Sci Rep 2012; 2: 657.
98. Wilmut I, Schnieke AE, McWhir J, Kind AJ, Campbell KH. Viable offspring derived from fetal and adult mammalian cells. Nature 1997; 385(6619): 810-813.
99. Cho HJ, Lee CS, Kwon YW, et al. Induction of pluripotent stem cells from adult somatic cells by protein-based reprogramming without genetic manipulation. Blood 2010; 116(3): 386-395.
100. Han J, Sachdev PS, Sidhu KS. A combined epigenetic and nongenetic approach for reprogramming human somatic cells. PLoS One 2010; 5(8): e12297.
101. Zhou H, Wu S, Joo JY, et al. Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell 2009; 4(5): 381-384.
102. Wadia JS, Dowdy SF. Protein transduction technology. Curr Opin Biotechnol 2002; 13(1): 52-56.
103. Kim D, Kim CH, Moon JI, et al. Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell 2009; 4(6): 472-476.
104. Takahashi K, Okita K, Nakagawa M, Yamanaka S. Induction of pluripotent stem cells from fibroblast cultures. Nat Protoc 2007; 2(12): 3081-3089.
105. Papapetrou EP, Tomishima MJ, Chambers SM, et al. Stoichiometric and temporal requirements of Oct4, Sox2, Klf4, and c-Myc expression for efficient human iPSC induction and differentiation. Proc Natl Acad Sci USA 2009; 106(31): 12759-12764.
106. Lee TH, Song SH, Kim KL, et al. Functional recapitulation of smooth muscle cells via induced pluripotent stem cells from human aortic smooth muscle cells. Circ Res 2010; 106(1): 120-128.
107. Kamata M, Liu S, Liang M, Nagaoka Y, Chen IS. Generation of human induced pluripotent stem cells bearing an anti-HIV transgene by a lentiviral vector carrying an internal murine leukemia virus promoter. Hum Gene Ther 2010; 21(11): 1555-1567.
108. Liao J, Wu Z, Wang Y, et al. Enhanced efficiency of generating induced pluripotent stem (iPS) cells from human somatic cells by a combination of six transcription factors. Cell Res 2008; 18(5): 600-603.
109. Zhao R, Daley GQ. From fibroblasts to iPS cells: induced pluripotency by defined factors. J Cell Biochem 2008; 105(4): 949-955.
110. Tsubooka N, Ichisaka T, Okita K, Takahashi K, Nakagawa M, Yamanaka S. Roles of Sall4 in the generation of pluripotent stem cells from blastocysts and fibroblasts. Genes Cells 2009; 14(6): 683-694.
111. Ruiz S, Panopoulos AD, Herrerias A, et al. A high proliferation rate is required for cell reprogramming and maintenance of human embryonic stem cell identity. Curr Biol 2011; 21(1): 45-52.
112. Edel MJ, Menchon C, Menendez S, Consiglio A, Raya A, Izpisua Belmonte JC. Rem2 GTPase maintains survival of human embryonic stem cells as well as enhancing reprogramming by regulating p53 and cyclin D1. Genes Dev 2010; 24(6): 561-573.
113. Kawamura T, Suzuki J, Wang YV, et al. Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature 2009; 460(7259): 1140-1144.
114. Marion RM, Strati K, Li H, et al. A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature 2009; 460(7259): 1149-1153.
115. Menendez S, Camus S, Izpisua Belmonte JC. P53: guardian of reprogramming. Cell Cycle 2010; 9(19): 3887-3891.
116. Hong H, Takahashi K, Ichisaka T, et al. Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature 2009; 460(7259): 1132-1135.
117. Yi L, Lu C, Hu W, Sun Y, Levine AJ. Multiple roles of p53-related pathways in somatic cell reprogramming and stem cell differentiation. Cancer Res 2012; 72(21): 5635-5645.
118. Mah N, Wang Y, Liao MC, et al. Molecular insights into reprogramming- initiation events mediated by the OSKM gene regulatory network. PLoS One 2011; 6(8): e24351.
119. Kim J, Lengner CJ, Kirak O, et al. Reprogramming of postnatal neurons into induced pluripotent stem cells by defined factors. Stem Cells 2011; 29(6): 992-1000.
120. Li H, Collado M, Villasante A, Strati K, Ortega S, Canamero M, Blasco MA, Serrano M. The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature 2009; 460 (7259): 1136-1139.
121. Raya A, Rodriguez-Piza I, Guenechea G, et al. Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. Nature 2009; 460(7251): 53-59.
122. Silva J, Barrandon O, Nichols J, Kawaguchi J, Theunissen TW, Smith A. Promotion of reprogramming to ground state pluripotency by signal inhibition. PLoS Biol 2008; 6(10): e253.
123. Li W, Zhou H, Abujarour R, et al. Generation of human-induced pluripotent stem cells in the absence of exogenous Sox2. Stem Cells 2009; 27(12): 2992-3000.
124. Banito A, Rashid ST, Acosta JC, et al. Senescence impairs successful reprogramming to pluripotent stem cells. Genes Dev 2009; 23(18): 2134-2139.
125. Muller LU, Milsom MD, Harris CE, et al. Overcoming reprogramming resistance of Fanconi anemia cells. Blood 2012; 119(23): 5449-5457.
126. Mallanna SK, Rizzino A. Emerging roles of microRNAs in the control of embryonic stem cells and the generation of induced pluripotent stem cells. Dev Biol 2010; 344(1): 16-25.
127. Wang Y, Baskerville S, Shenoy A, Babiarz JE, Baehner L, Blelloch R. Embryonic stem cell-specific microRNAs regulate the G1-S transition and promote rapid proliferation. Nat Genet 2008; 40(12): 1478-1483.
128. Judson RL, Babiarz JE, Venere M, Blelloch R. Embryonic stem cell-specific microRNAs promote induced pluripotency. Nat Biotechnol 2009; 27(5): 459-461.
129. Card DA, Hebbar PB, Li L, et al. Oct4/Sox2-regulated miR-302 targets cyclin D1 in human embryonic stem cells. Mol Cell Biol 2008; 28(20): 6426-6438.
130. Marson A, Levine SS, Cole MF, et al. Connecting microRNA genes to the core transcriptional regulatory circuitry of embryonic stem cells. Cell 2008; 134(3): 521-533.
131. Lin SL, Chang DC, Chang-Lin S, et al. Mir-302 reprograms human skin cancer cells into a pluripotent ES-cell-like state. RNA 2008; 14(10): 2115-2124.
132. Suh MR, Lee Y, Kim JY, et al. Human embryonic stem cells express a unique set of microRNAs. Dev Biol 2004; 270(2): 488-498.
133. Wilson KD, Venkatasubrahmanyam S, Jia F, Sun N, Butte AJ, Wu JC. MicroRNA profiling of human-induced pluripotent stem cells. Stem Cells Dev 2009; 18(5): 749-758.
134. Lin SL, Chang DC, Ying SY, Leu D, Wu DT. MicroRNA miR-302 inhibits the tumorigenecity of human pluripotent stem cells by coordinate suppression of the CDK2 and CDK4/6 cell cycle pathways. Cancer Res 2010; 70(22): 9473-9482.
135. Yoshida Y, Takahashi K, Okita K, Ichisaka T, Yamanaka S. Hypoxia enhances the generation of induced pluripotent stem cells. Cell Stem Cell 2009; 5(3): 237-241.
136. Ezashi T, Das P, Roberts RM. Low O2 tensions and the prevention of differentiation of hES cells. Proc Natl Acad Sci USA 2005; 102(13): 4783-4788
137. Morrison SJ, Csete M, Groves AK, Melega W, Wold B, Anderson DJ. Culture in reduced levels of oxygen promotes clonogenic sympathoadrenal differentiation by isolated neural crest stem cells. J Neurosci 2000; 20(19): 7370-7376.
138. Forristal CE, Wright KL, Hanley NA, Oreffo RO, Houghton FD. Hypoxia inducible factors regulate pluripotency and proliferation in human embryonic stem cells cultured at reduced oxygen tensions. Reproduction 2010; 139(1): 85-97.
139. Mikkelsen TS, Hanna J, Zhang X, et al. Dissecting direct reprogramming through integrative genomic analysis. Nature 2008; 454(7200): 49-55.
140. Esteban MA, Wang T, Qin B, et al. Vitamin C enhances the generation of mouse and human induced pluripotent stem cells. Cell Stem Cell 2010; 6(1): 71-79.
141. Chung TL, Brena RM, Kolle G, et al. Vitamin C promotes widespread yet specific DNA demethylation of the epigenome in human embryonic stem cells. Stem Cells 2010; 28(10): 1848-1855.
142. Picanco-Castro V, Russo-Carbolante E, Reis LC, et al. Pluripotent reprogramming of fibroblasts by lentiviral mediated insertion of SOX2, C-MYC, and TCL-1A. Stem Cells Dev 2011; 20(1): 169-180.
143. Laine J, Kunstle G, Obata T, Sha M, Noguchi M. The protooncogene TCL1 is an Akt kinase coactivator. Mol Cell 2000; 6(2): 395-407.
144. Moschidou D, Mukherjee S, Blundell MP, et al. Valproic Acid Confers Functional Pluripotency to Human Amniotic Fluid Stem Cells in a Transgene-free Approach. Mol Ther 2012; 20(10): 1953-1967.
145. Mali P, Ye Z, Hommond HH, et al. Improved efficiency and pace of generating induced pluripotent stem cells from human adult and fetal fibroblasts. Stem Cells 2008; 26(8): 1998-2005.
146. Feldman N, Gerson A, Fang J, et al. G9a-mediated irreversible epigenetic inactivation of Oct-3/4 during early embryogenesis. Nat Cell Biol 2006; 8(2): 188-194.
147. Defoort EN, Kim PM, Winn LM. Valproic acid increases conservative homologous recombination frequency and reactive oxygen species formation: a potential mechanism for valproic acid-induced neural tube defects. Mol Pharmacol 2006; 69(4): 1304-1310.
148. Sha K, Winn LM. Characterization of valproic acid-initiated homologous recombination. Birth Defects Res B Dev Reprod Toxicol 2010; 89(2): 124-132.
149. Purrucker JC, Fricke A, Ong MF, Rube C, Rube CE, Mahlknecht U. HDAC inhibition radiosensitizes human normal tissue cells and reduces DNA Double-Strand Break repair capacity. Oncol Rep 2010; 23(1): 263-269.
150. Elenbaas B, Spirio L, Koerner F, et al. Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev 2001; 15(1): 50-65.
151. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA. Creation of human tumour cells with defined genetic elements. Nature 1999; 400(6743): 464-468.
152. Lundberg AS, Randell SH, Stewart SA, et al. Immortalization and transformation of primary human airway epithelial cells by gene transfer. Oncogene 2002; 21(29): 4577-4586.
153. Nakagawa M, Takizawa N, Narita M, Ichisaka T, Yamanaka S. Promotion of direct reprogramming by transformation-deficient Myc. Proc Natl Acad Sci USA 2010; 107(32): 14152-14157.
154. Hockemeyer D, Soldner F, Cook EG, Gao Q, Mitalipova M, Jaenisch R. A drug-inducible system for direct reprogramming of human somatic cells to pluripotency. Cell Stem Cell 2008; 3(3): 346-353.
155. Lowry WE, Richter L, Yachechko R, et al. Generation of human induced pluripotent stem cells from dermal fibroblasts. Proc Natl Acad Sci USA 2008; 105(8): 2883-2888.
156. Vallier L, Touboul T, Brown S, et al. Signaling pathways controlling pluripotency and early cell fate decisions of human induced pluripotent stem cells. Stem Cells 2009; 27(11): 2655-2666.
157. Yehezkel S, Rebibo-Sabbah A, Segev Y, et al. Reprogramming of telomeric regions during the generation of human induced pluripotent stem cells and subsequent differentiation into fibroblast-like derivatives. Epigenetics 2011; 6(1): 63-75.
158. Choi KD, Yu J, Smuga-Otto K, et al. Hematopoietic and endothelial differentiation of human induced pluripotent stem cells. Stem Cells 2009; 27(3): 559-567.
159. Oda Y, Yoshimura Y, Ohnishi H, et al. Induction of pluripotent stem cells from human third molar mesenchymal stromal cells. J Biol Chem 2010; 285(38): 29270-29278.
160. Tamaoki N, Takahashi K, Tanaka T, et al. Dental pulp cells for induced pluripotent stem cell banking. J Dent Res 2010; 89(8): 773-778.
161. Nagata S, Toyoda M, Yamaguchi S, et al. Efficient reprogramming of human and mouse primary extra-embryonic cells to pluripotent stem cells. Genes Cells 2009; 14(12): 1395-1404.
162. Ye L, Chang JC, Lin C, Sun X, Yu J, Kan YW. Induced pluripotent stem cells offer new approach to therapy in thalassemia and sickle cell anemia and option in prenatal diagnosis in genetic diseases. Proc Natl Acad Sci USA 2009; 106(24): 9826-9830.
163. Zhao HX, Li Y, Jin HF, et al. Rapid and efficient reprogramming of human amnion-derived cells into pluripotency by three factors OCT4/SOX2/NANOG. Differentiation 2010; 80(2-3): 123-129.
164. Ho PJ, Yen ML, Lin JD, et al. Endogenous KLF4 expression in human fetal endothelial cells allows for reprogramming to pluripotency with just OCT3/4 and SOX2--brief report. Arterioscler Thromb Vasc Biol 2010; 30(10): 1905-1907.
165. Hester ME, Song S, Miranda CJ, Eagle A, Schwartz PH, Kaspar BK. Two factor reprogramming of human neural stem cells into pluripotency. PLoS One 2009; 4(9): e7044.
166. Kim JB, Greber B, Arauzo-Bravo MJ, et al. Direct reprogramming of human neural stem cells by OCT4. Nature 2009; 461(7264): 649-653.
167. Giorgetti A, Montserrat N, Aasen T, et al. Generation of induced pluripotent stem cells from human cord blood using OCT4 and SOX2. Cell Stem Cell 2009; 5(4): 353-357.
168. Eminli S, Foudi A, Stadtfeld M, et al. Differentiation stage determines potential of hematopoietic cells for reprogramming into induced pluripotent stem cells. Nat Genet 2009; 41(9): 968-976.
169. Streckfuss-Bomeke K, Wolf F, Azizian A, et al. Comparative study of human-induced pluripotent stem cells derived from bone marrow cells, hair keratinocytes, and skin fibroblasts. Eur Heart J 2012; [Epub ahead of print].
170. Aoi T, Yae K, Nakagawa M, et al. Generation of pluripotent stem cells from adult mouse liver and stomach cells. Science 2008; 321(5889): 699-702.
171. Chan EM, Ratanasirintrawoot S, Park IH, et al. Live cell imaging distinguishes bona fide human iPS cells from partially reprogrammed cells. Nat Biotechnol 2009; 27(11): 1033-1037.
172. Feng Q, Lu SJ, Klimanskaya I, et al. Hemangioblastic derivatives from human induced pluripotent stem cells exhibit limited expansion and early senescence. Stem Cells 2010; 28(4): 704-712.
173. Hu BY, Weick JP, Yu J, et al. Neural differentiation of human induced pluripotent stem cells follows developmental principles but with variable potency. Proc Natl Acad Sci USA 2010; 107(9): 4335-4340.
174. Bock C, Kiskinis E, Verstappen G, et al. Reference Maps of human ES and iPS cell variation enable high-throughput characterization of pluripotent cell lines. Cell 2011; 144(3): 439-452.
175. Doi A, Park IH, Wen B, et al. Differential methylation of tissueand cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat Genet 2009; 41(12): 1350-1353.
176. Kim K, Doi A, Wen B, et al. Epigenetic memory in induced pluripotent stem cells. Nature 2010; 467(7313): 285-290.
177. Kim K, Zhao R, Doi A, et al. Donor cell type can influence the epigenome and differentiation potential of human induced pluripotent stem cells. Nat Biotechnol 2011; 29(12): 1117-1119.
178. Ohi Y, Qin H, Hong C, et al. Incomplete DNA methylation underlies a transcriptional memory of somatic cells in human iPS cells. Nat Cell Biol 2011; 13(5): 541-549.
179. Ball MP, Li JB, Gao Y, et al. Targeted and genome-scale strategies reveal gene-body methylation signatures in human cells. Nat Biotechnol 2009; 27(4): 361-368.
180. Stadtfeld M, Apostolou E, Akutsu H, et al. Aberrant silencing of imprinted genes on chromosome 12qF1 in mouse induced pluripotent stem cells. Nature 2010; 465(7295): 175-181.
181. Boulting GL, Kiskinis E, Croft GF, et al. A functionally characterized test set of human induced pluripotent stem cells. Nat Biotechnol 2011; 29(3): 279-286.
182. Lister R, Pelizzola M, Kida YS, et al. Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Nature 2011; 471(7336): 68-73.
183. Polo JM, Liu S, Figueroa ME, et al. Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. Nat Biotechnol 2010; 28(8): 848-855.
184. Ruiz S, Diep D, Gore A, et al. Identification of a specific reprogramming- associated epigenetic signature in human induced pluripotent stem cells. Proc Natl Acad Sci USA 2012; 109(40): 16196-16201.
185. Gore A, Li Z, Fung HL, et al. Somatic coding mutations in human induced pluripotent stem cells. Nature 2011; 471(7336): 63-67.
186. Hussein SM, Batada NN, Vuoristo S, et al. Copy number variation and selection during reprogramming to pluripotency. Nature 2011; 471(7336): 58-62.
187. Hacein-Bey-Abina S, Garrigue A, Wang GP, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 2008; 118(9): 3132-3142.
188. Howe SJ, Mansour MR, Schwarzwaelder K, et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 2008; 118(9): 3143-3150.
189. Laurent LC, Ulitsky I, Slavin I, et al. Dynamic changes in the copy number of pluripotency and cell proliferation genes in human ESCs and iPSCs during reprogramming and time in culture. Cell Stem Cell 2011; 8(1): 106-118.
190. Mayshar Y, Ben-David U, Lavon N, et al. Identification and classification of chromosomal aberrations in human induced pluripotent stem cells. Cell Stem Cell 2010; 7(4): 521-531.
191. Abyzov A, Mariani J, Palejev D, et al. Somatic copy number mosaicism in human skin revealed by induced pluripotent stem cells. Nature 492(7429): 438-442.
192. Gourraud PA, Gilson L, Girard M, Peschanski M. The role of human leukocyte antigen matching in the development of multiethnic haplobank of induced pluripotent stem cell lines. Stem Cells 30(2): 180-186.
193. Handel EM, Cathomen T. Zinc-finger nuclease based genome surgery: it's all about specificity. Curr Gene Ther 2011; 11(1): 28-37.
194. Silva G, Poirot L, Galetto R, et al. Meganucleases and other tools for targeted genome engineering: perspectives and challenges for gene therapy. Curr Gene Ther 2011; 11(1): 11-27.
195. Bednarski C, Händel E, Cathomen T. Targeted genome modifications with designer nucleases, In: The Clinibook: clinical gene transfert state of the art, O. C-H, Ed.; EDK: Paris, 2012; p 354-367.
196. Pâques F, Smith J. Targeted genome engineering approches based on rare-cutting endonucleases: a tentative summary, In: The Clinibook: clinical gene transfert state of the art, O. C-H, Ed.; EDK: Paris, 2012; p 341-353.
197. Li H, Haurigot V, Doyon Y, et al. In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature 2011; 475(7355): 217-221.
198. Reik A, Zhou Y, Hamlett A, et al. Zinc Finger Nucleases Targeting the Glucocorticoid Receptor Allow IL-13 Zetakine Transgenic CTLs To Kill Glioblastoma Cells In vivo in the Presence of Immunosuppressing Glucocorticoids. Mol Ther 2008; 16(1s): 13-S14.
199. Holt N, Wang J, Kim K, et al. Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol 2010; 28(8): 839-847.
200. Perez EE, Wang J, Miller JC, et al. Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol 2008; 26(7): 808-816.
201. Yusa K, Rashid ST, Strick-Marchand H, et al. Targeted gene correction of alpha1-antitrypsin deficiency in induced pluripotent stem cells. Nature 2011; 478(7369): 391-394.
202. Hockemeyer D, Wang H, Kiani S, et al. Genetic engineering of human pluripotent cells using TALE nucleases. Nat Biotechnol 2011; 29(8): 731-734.
203. Ramalingam S, London V, Kandavelou K, et al. Generation and genetic engineering of human induced pluripotent stem cells using designed zinc finger nucleases. Stem Cells Dev 2013; 22(4): 595-610.